Stay updated on Pembrolizumab in HER2+ Gastric Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.

Latest updates to the Pembrolizumab in HER2+ Gastric Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded a 'Gastric cancer' tag and a link to the Genetic and Rare Diseases Information Center; page revision updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check18 days agoChange DetectedA new revision label 'Revision: v3.4.1' appears and the previous 'Revision: v3.4.0' label is removed; this is a minor version update not affecting trial details.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page adds a glossary toggle and new metadata fields (Last Update Submitted that Met QC Criteria, Last Update Posted) plus an updated revision label (v3.4.0). It removes older items (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

- Check39 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedThe Study Details page has expanded the Contacts and Locations section with a comprehensive list of new sites across the United States and other countries. This increases accessibility for potential participants by showing where enrollment is available.SummaryDifference3%

- Check75 days agoChange DetectedCompleted status was added and the previous 'Active, not recruiting' status was removed. The latest update was posted in November 2025, indicating the trial has finished enrollment and data collection.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HER2+ Gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.